213764-00-2

Upstream product

• 371-41-5 4-Fluorophenol 
• 213764-20-6 2-benzyl-4-bromo-5-(4-methylsulfonyl)phenyl-2H-pyridazin-3-one 
• 7732-18-5 water 
• 213763-99-6 2-Benzyl-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone 
• 98546-51-1 (4-thiomethoxyphenyl)boronic acid 
• 552865-15-3 4-bromo-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one 
• 552865-14-2 3-bromo-5-hydroxy-4-(4-methanesulfonyl-phenyl)-5H-furan-2-one 
• 552865-13-1 3-bromo-4-(4-methanesulfonyl-phenyl)-5H-furan-2-one 
• 162012-28-4 4-(4-(methylthio)phenyl)furan-2(5H)-one 

Downstream Products

• 213764-17-1 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-hydropyridazin-3-one 

Relevant academic research and scientific papers

PYRIDAZINONES AS INHIBITORS OF CYCLOOXYGENASE-2

The invention encompasses the pyridazin-3-one compounds of formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a

Pyridazinones as selective cyclooxygenase-2 inhibitors

Pyridazinone was found to be an excellent core template for selective COX-2 inhibitors. Two potent, selective and orally active COX-2 inhibitors, which were highly efficacious in rat paw edema and rat pyresis models, have been obtained.

Prostaglandin endoperoxide H synthase biosynthesis inhibitors

The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

Pyridazinones as inhibitors of cyclooxygenase-2

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.